Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037527 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04037527 is a Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 9 participants.
The verdict
NCT04037527, a Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
Interventions
- DRUG Docetaxel
- PROCEDURE Surgical Resection
- DRUG Gemcitabine
- RADIATION Radiation
- OTHER Blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2024-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04037527
The ClinicalTrials.gov registry entry for NCT04037527 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT04037527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04037527 about?
NCT04037527 is a clinical study titled "Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities". The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
What is the current status of trial NCT04037527?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-08-18. Estimated completion is 2024-06-18.
What interventions are being tested in trial NCT04037527?
The interventions under investigation include: Docetaxel (DRUG), Surgical Resection (PROCEDURE), Gemcitabine (DRUG), Radiation (RADIATION), Blood draws (OTHER).
Who is sponsoring clinical trial NCT04037527?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.